February 2016 | Precision Medicine in Oncology

Is PD-L1 Just the Tip of the Iceberg?

February 01, 2016

PD-1 and PD-L1 inhibition offers the possibility for precision immuno-oncology through the application of biomarkers that predict the immune systems response. This principle has been demonstrated by two of the most recent FDA approvals for patients with lung cancer.